Abstract
Malignant pleural effusions (MPEs) are an important cause of cancer-related mortality and morbidity. It is a heterogeneous group of conditions, which leads to debilitating symptoms and confers a poor prognosis. Recent well-designed randomized trials have provided a broader evidence base for an expanding range of treatment options. Together, with new prognostic scoring systems and a greater understanding of how different patient phenotypes respond to treatment, this allows greater personalization of management. This article will discuss the current evidence on evaluation and management of MPEs.
| Original language | English |
|---|---|
| Pages (from-to) | 105-114 |
| Number of pages | 10 |
| Journal | Therapeutic Advances in Respiratory Disease |
| Volume | 11 |
| Issue number | 2 |
| Early online date | 24 Oct 2016 |
| DOIs | |
| Publication status | Published - 1 Feb 2017 |
UN SDGs
This output contributes to the following UN Sustainable Development Goals (SDGs)
-
SDG 3 Good Health and Well-being
Research Groups and Themes
- Academic Respiratory Unit
Keywords
- indwelling pleural catheter
- malignant
- Mesothelioma
- Pleural effusion
- pleurodesis
Fingerprint
Dive into the research topics of 'Current best practice in the evaluation and management of malignant pleural effusions'. Together they form a unique fingerprint.Cite this
- APA
- Author
- BIBTEX
- Harvard
- Standard
- RIS
- Vancouver